

## **Supplementary Materials**

### **Pectin Nanoparticle-Loaded Soft Coral *Nephthea* sp. Extract as *In Situ* Gel Enhances Chronic Wound Healing: *In Vitro*, *In Vivo*, and *In Silico* Studies**

Nevine H. Hassan <sup>1</sup>, Seham S. El-Hawary <sup>2</sup>, Mahmoud Emam <sup>3</sup>, Mohamed A. Rabeh <sup>4</sup>, Mohamed A. Tantawy <sup>5,6,7</sup>, Mohamed Seif <sup>8</sup>, Radwa M. A. Abd-Elal <sup>9,\*</sup>, Gerhard Bringmann <sup>10</sup>, Usama Ramadan Abdelmohsen <sup>11,12,\*</sup> and Nabil M. Selim <sup>2,\*</sup>



**A****B**

Figure S1. Total ion chromatogram of *Nephthea* sp. extract recorded in (A) positive ionization mode and (B) negative ionization mode.




Figure S2. ESI-MS as well as <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra of compound 12 (bis-(2-ethylhexyl)-phthalate) measured in CDCl<sub>3</sub>




Figure S3. ESI-MS spectra of compound **18** (oleic acid) measured in  $CDCl_3$






Figure S4. ESI-MS spectra of compound **20** (arachidic acid) measured in  $CDCl_3$



**Figure S5.**  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR spectra of compound **24** (nervonic acid) measured in  $\text{CDCl}_3$

**Table S1.** Medicinal- chemistry properties for the most active compounds.

Parameter	Compound		Comment
	Chabrolohydroxybenzoquinone F (13)	Isogosterone B (9)	
QED	0.245	0.416	A measure of drug-likeness based on the concept of desirability; attractive: > 0.67; unattractive: 0.49~0.67; too complex: < 0.34
Synth	4.146	5.755	The synthetic accessibility score is designed to estimate the ease of synthesis of drug-like molecules. SA score > 6: difficult to synthesize; SA score < 6: easy to synthesize
Fsp <sup>3</sup>	0.481	0.759	The number of sp <sup>3</sup> hybridized carbons / total carbon count, correlating with melting point and solubility. Fsp <sup>3</sup> ≥ 0.42 is considered a suitable value
MCE-18	28	114.529	MCE-18 stands for medicinal chemistry evolution. MCE-18 ≥ 45 is considered a suitable value
Pfizer	<u>Accepted</u>	<u>Accepted</u>	Log P > 3; TPSA < 75; compounds with a high log P (> 3) and low TPSA (< 75) are likely to be toxic

**Table S2.** Absorption profile for the most active compounds.

Parameter	Compound		Comment
	Chabrolohydroxybenzoquinone F (13)	Isogosterone B (9)	
HIA	0.617	0.035	Human intestinal absorption. More close to 1 considered to be highly absorbed by intestine
Caco-2 permeability	-4.802	-4.656	Toxicity on normal cells, such as Caco-2 cells. Optimal: higher than -5.15 Log unit
MDCK permeability	3.23E-05	2.11E-05	Toxicity on normal cells such as MDCK cells; low permeability: < 2 × 10 <sup>6</sup> cm/s medium permeability: 2–20 × 10 <sup>6</sup> cm/s high passive permeability: > 20 × 10 <sup>6</sup> cm/s

**Table S3.** Distribution properties for the most active compounds.

Parameter	Compound		Comment
	Chabrolohydroxybenzoquinone F (13)	Isogosterone B (9)	
BBB	0.019	0.974	Blood-brain barrier (BBB) penetration More close to 1 considered to be highly permeable by BBB
PPB	98.61%	86.57%	Plasma protein binding (PPB) Optimal drugs should have a value < 90%.
VD <sub>ss</sub>	0.476	0.931	Volume distribution (VD) Optimal: 0.04-20 L/kg
Fu	1.08%	8.88%	The fraction unbound (Fu) in plasma; low: < 5%; middle: 5~20%; high: > 20%

**Table S4.** Metabolism profile for the most active compounds.

Parameter	Compounds		Comment
	Chabrolohydroxybenzoquinone F (13)	Isogosterone B (9)	
CYP1A2-inh	0.267	0.003	Closer to 1: considered to be an inhibitor.
CYP1A2-sub	0.36	0.106	Closer to 1: considered to be a substrate.
CYP2C19-inh	0.449	0.024	Closer to 1: considered to be an inhibitor.
CYP2C19-sub	0.526	0.721	Closer to 1: considered to be a substrate.
CYP2C9-inh	0.595	0.09	Closer to 1: considered to be an inhibitor.
CYP2C9-sub	0.944	0.107	Closer to 1: considered to be a substrate.
CYP2D6-inh	0.905	0.005	Closer to 1: considered to be an inhibitor.
CYP2D6-sub	0.103	0.047	Closer to 1: considered to be a substrate.
CYP3A4-inh	0.809	0.732	Closer to 1: considered to be an inhibitor.
CYP3A4-sub	0.215	0.7	Closer to 1: considered to be a substrate.

**Table S5.** Excretion for the most active compounds.

Parameter	Compounds		Comment
	Chabrolohydroxybenzoquinone F (13)	Isogosterone B (9)	
CL	11.78	12.429	Clearance (CL): a compound that has a clearance > 15 mL/min/kg is considered to have a high clearance, while a compound that has a clearance from 5 to 15 mL/min/kg has a moderate clearance, and a compound that has a clearance < 5 mL/min/kg has a low clearance.
T12	0.484	0.485	Closer to 1: considered to have a long half-life.